CVA Family Office’s Novo Nordisk NVO Stock Holding History

CVA Family Office’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.23K	Sell	130 -100	-43%	-$4.3K	﹤0.01%	1190
2026 Q1	$8.45K	Hold	230	–	–	﹤0.01%	1049
2025 Q4	$11.7K	Hold	230	–	–	﹤0.01%	776
2025 Q3	$12.8K	Hold	230	–	–	﹤0.01%	765
2025 Q2	$15.9K	Hold	230	–	–	﹤0.01%	736
2025 Q1	$16K	Hold	230	–	–	﹤0.01%	721
2024 Q4	$19.8K	Hold	230	–	–	﹤0.01%	679
2024 Q3	$27.4K	Sell	230 -1,652	-88%	-$220K	﹤0.01%	605
2024 Q2	$269K	Buy	1,882 +100	+6%	+$13.3K	0.05%	202
2024 Q1	$229K	Hold	1,782	–	–	0.04%	219
2023 Q4	$184K	Buy	+1,782	New	+$176K	0.04%	243
2023 Q3	–	Sell	-1,652	Closed	-$134K	–	708
2023 Q2	$134K	Hold	1,652	–	–	0.03%	273
2023 Q1	$131K	Hold	1,652	–	–	0.03%	272
2022 Q4	$112K	Hold	1,652	–	–	0.03%	277
2022 Q3	$82K	Hold	1,652	–	–	0.02%	272
2022 Q2	$92K	Hold	1,652	–	–	0.03%	258
2022 Q1	$92K	Sell	1,652 -820	-33%	-$42.1K	0.02%	276
2021 Q4	$138K	Buy	+2,472	New	+$134K	0.03%	200
2021 Q3	–	Sell	-2,472	Closed	-$104K	–	707
2021 Q2	$104K	Buy	+2,472	New	+$95.8K	0.03%	236

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

CVA Family Office's NVO Position: Q2 2026 in Review

CVA Family Office reduced its Novo Nordisk (NVO) stake by 43% in Q2 2026, selling an estimated $4.3K and leaving 130 shares worth $6.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1190.

CVA Family Office first reported a position in NVO in Q2 2021 and has held it in 19 quarters since. The position peaked at $269K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

CVA Family Office held 130 shares of Novo Nordisk worth $6.23K as of Q2 2026.
CVA Family Office sold 100 Novo Nordisk shares in Q2 2026, an estimated $4.3K.
Novo Nordisk made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1190 holding.
CVA Family Office first reported a position in Novo Nordisk in Q2 2021 and has held it in 19 quarters since.
CVA Family Office's Novo Nordisk position peaked at $269K in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.